This week, the overall grades of nine biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
EPIRUS Biopharmaceuticals, Inc. (EPRS) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. For Portfolio Grader’s specific subcategory of Earnings Revisions, EPRS also gets an F. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of EPRS stock.
This week, Ohr Pharmaceutical Inc (OHRP) drops from a C to a D rating. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. Trade volume is up 3740.7% from the previous week. To get an in-depth look at OHRP, get Portfolio Grader’s complete analysis of OHRP stock.
Trius Therapeutics, Inc. (TSRX) experiences a ratings drop this week, going from last week’s C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
Slipping from a C to a D rating, Vical Incorporated (VICL) takes a hit this week. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at VICL, get Portfolio Grader’s complete analysis of VICL stock.
Tenax Therapeutics, Inc. (TENX) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). The stock receives F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. Trade volume is up 441.3% from the previous week. The stock has a trailing PE Ratio of 106.70. For more information, get Portfolio Grader’s complete analysis of TENX stock.
Synergy Pharmaceuticals, Inc. (SGYP) is having a tough week. The company’s rating falls from a D to an F. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of March 4, 2015, 14.3% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. Shares of the stock have been changing hands at an unusually rapid pace, up 2854.4% from the week prior. To get an in-depth look at SGYP, get Portfolio Grader’s complete analysis of SGYP stock.
Verastem, Inc. (VSTM) earns an F this week, moving down from last week’s grade of D. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. Shares of the stock are being traded at a very rapid pace, up 950.2% from the week prior. For more information, get Portfolio Grader’s complete analysis of VSTM stock.
The rating of Celldex Therapeutics, Inc. (CLDX) declines this week from a C to a D. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of March 4, 2015, 23.7% of outstanding Celldex Therapeutics, Inc. shares were held short. To get an in-depth look at CLDX, get Portfolio Grader’s complete analysis of CLDX stock.
This week, Trevena, Inc.’s (TRVN) rating worsens to a D from the company’s C rating a week ago. The stock gets F’s in Equity and Cash Flow. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. For more information, get Portfolio Grader’s complete analysis of TRVN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
